The seed money will go toward a new network focused on community public health research in Indiana. The network will include community and health groups and focus on research that will benefit people across the state.
Only a few patients receive promising COVID treatments dailynews.lk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailynews.lk Daily Mail and Mail on Sunday newspapers.
by: Dr. Mary Gillis, D.Ed.
Posted:
Mar 11, 2021 / 09:16 AM EST
INDIANAPOLIS (WISH) They have been at the forefront in the fight against the coronavirus and now the development of a new combination treatment, Eli Lilly & Company could bring us one step close to winning the battle.
On Wednesday, the company announced results from their BLAZE-1 Phase 3 clinical trial involving high risk, symptomatic patients recently diagnosed with COVID-19. News 8 spoke with Janelle Sabo, COVID-19 therapeutics platform leader at Lilly, about the findings.
Gillis: We’re so excited to have you here. Thank you so much and congratulations. Tell us about the results of this trial and why the combination treatment?
More than 800 people at high risk for hospitalization have received antibody treatments to fight mild or moderate cases of COVID-19 since a regional infusion center opened in Mishawaka in December.
The Northern Indiana COVID Infusion Center, 60202 Bodnar Lane, offers the monoclonal antibody Bamlanivimab, produced by Lilly, and an antibody cocktail produced by Regeneron to patients who are 65 and older, or those with other risk factors such as obesity and diabetes.
Lilly chose the St. Joseph Health System site, at Elm and Jackson roads, to set up one of three regional infusion centers across Indiana in an effort to distribute antibody treatments that have received emergency approval from the FDA.